Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …

Abstract Characterization of tumors utilizing next‐generation sequencing methods, including
assessment of the number of somatic mutations (tumor mutational burden [TMB]), is currently …

Background Tumor mutational burden (TMB), defined as the number of somatic mutations
per megabase of interrogated genomic sequence, demonstrates predictive biomarker …

Accurate identification of patients with solid tumors likely to respond to immunotherapy is
crucial. Tumor mutational burden (TMB) measures the number of somatic mutations in a …

Immunotherapies based on immune checkpoint inhibitors are emerging as an innovative
treatment for different types of advanced cancers. While the utility of immune checkpoint …

Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …

Background Tumor mutational burden (TMB) measurements aid in identifying patients who
are likely to benefit from immunotherapy; however, there is empirical variability across panel …

Assessment of Tumor Mutational Burden (TMB) for response stratification of cancer patients
treated with immune checkpoint inhibitors is emerging as a new biomarker. Commonly …

Clinical evidence demonstrates that treatment with immune checkpoint inhibitor
immunotherapy agents can have considerable benefit across multiple tumours. However …

Tumor mutational burden (TMB) represents a new determinant of clinical benefit from
immune checkpoint blockade that identifies responders independent of PD‐L1 expression …